AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37734856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 37734857 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment in high HB group
Number of subjects: 727
Study 37734857 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment in low HB group
Number of subjects: 727
Study 37734857 — intervention group
Group type: COMPARATOR
Intervention: Usual care in low HB group
Number of subjects: 727
Study 37734880 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone (0.5 mg/kg/day) plus rituximab (375 mg/m2)
Number of subjects: 140
Study 37734880 — intervention group
Group type: COMPARATOR
Intervention: High-dose glucocorticoids plus rituximab
Number of subjects: 140
Study 37734880 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone plus rituximab
Number of subjects: 140
Study 37734883 — intervention group
Group type: EXPERIMENTAL
Intervention: EmpaTeach intervention
Number of subjects: 97
Study 37734883 — intervention group
Group type: COMPARATOR
Intervention: Corporal punishment
Number of subjects: 97
Study 37734895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sensitive topics (n=474)
Number of subjects: 919
Study 37734895 — intervention group
Group type: COMPARATOR
Intervention: Patients without sensitive topics (n=445)
Number of subjects: 919
Study 37734896 — intervention group
Group type: EXPERIMENTAL
Intervention: REDUCE protocol (early de-resuscitation protocol)
Number of subjects: 0
Study 37734896 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 0
Study 37734899 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected risk factors (dialysis prescriptions, serum potassium testing frequency, patient characteristics, medication usage)
Number of subjects: 300
Study 37734899 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium management patterns
Number of subjects: 300
Study 37734899 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium levels ≥6.0 and ≥6.5 mmol/L
Number of subjects: 300
Study 37734951 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) with thin bronchoscopes, radial endobronchial ultrasound (rEBUS), and guide sheath (GS).
Number of subjects: 479
Study 37734951 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) with thin bronchoscopes.
Number of subjects: 479
Study 37734951 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB).
Number of subjects: 479
Study 37735023 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized group (n = 449) with additional 1.5 L PEG for high-risk patients
Number of subjects: 900
Study 37735023 — intervention group
Group type: COMPARATOR
Intervention: Standard group (n = 451) without additional PEG
Number of subjects: 900
Study 37735023 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized group (n = 449) for high-risk patients
Number of subjects: 900
Study 37735023 — intervention group
Group type: COMPARATOR
Intervention: Standard group (n = 451) for high-risk patients
Number of subjects: 900
Study 37735023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 900
Study 37735271 — intervention group
Group type: EXPERIMENTAL
Intervention: InternalBrace™-augmented repair (ACL-IB)
Number of subjects: 85
Study 37735271 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACL-R)
Number of subjects: 85
Study 37735271 — intervention group
Group type: COMPARATOR
Intervention: InternalBrace™-augmented repair (ACL-IB) and ACL reconstruction (ACL-R)
Number of subjects: 85
Study 37735274 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain insulin action
Number of subjects: 0
Study 37735274 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 37735385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish cartilage hydrolysate (FCH)
Number of subjects: 33
Study 37735385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish cartilage hydrolysate (FCH) metabolites
Number of subjects: 33
Study 37735443 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-enabled support (TEACH) intervention with real-time audit and feedback
Number of subjects: 9900
Study 37735443 — intervention group
Group type: COMPARATOR
Intervention: Usual supervisor-led audit and feedback intervention
Number of subjects: 9900
Study 37735517 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Osteoarthritis Self-Management Programme (SOASP)
Number of subjects: 143
Study 37735543 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 13
Study 37735588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells
Number of subjects: 19
Study 37735634 — intervention group
Group type: EXPERIMENTAL
Intervention: mFFX (4 cycles) or Gemcitabine/Nab-Paclitaxel (6 doses)
Number of subjects: 256
Study 37735634 — intervention group
Group type: EXPERIMENTAL
Intervention: mFFX (2 cycles) or Gemcitabine/Nab-Paclitaxel (3 doses) + iHD-SBRT (35 to 55 Gy in 5 fractions) + mFFX (2 cycles) or Gemcitabine/Nab-Paclitaxel (3 doses)
Number of subjects: 256
Study 37735634 — intervention group
Group type: COMPARATOR
Intervention: mFFX (4 additional cycles) or Gemcitabine/Nab-Paclitaxel (6 additional doses)
Number of subjects: 256
Study 37735664 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent exercise training during adjuvant chemotherapy
Number of subjects: 8
Study 37735664 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline, post-intervention, and 3-month follow-up assessments
Number of subjects: 8
Study 37735668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) (0.05 ml; cell concentration: 1.5 × 10^6 cells)
Number of subjects: 5
Study 37735668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 5
Study 37735690 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive assist-as-needed (AAN) control using the Lokomat
Number of subjects: 27
Study 37735706 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberative engagement process
Number of subjects: 0
Study 37735706 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation of staff for deliberations
Number of subjects: 0
Study 37735706 — intervention group
Group type: EXPERIMENTAL
Intervention: Briefing materials
Number of subjects: 0
Study 37735706 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating a comfortable environment for staff
Number of subjects: 0
Study 37735756 — intervention group
Group type: EXPERIMENTAL
Intervention: DC:Ad-S vaccine administered 7 to 30 days prior to stem cell collection and 20 to 34 days after ASCT
Number of subjects: 14
Study 37735756 — intervention group
Group type: EXPERIMENTAL
Intervention: DC:Ad-S vaccine
Number of subjects: 14
Study 37735841 — intervention group
Group type: EXPERIMENTAL
Intervention: GL-Asp (0.2 U/kg)
Number of subjects: 187
Study 37735841 — intervention group
Group type: EXPERIMENTAL
Intervention: GL-Lis (0.2 U/kg)
Number of subjects: 187
Study 37735841 — intervention group
Group type: EXPERIMENTAL
Intervention: GL-Gla (0.5 U/kg)
Number of subjects: 187
Study 37736522 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cannabis use in PLWH
Number of subjects: 48
Study 37736522 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV chronicity (years since HIV diagnosis)
Number of subjects: 48
Study 37736603 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Number of subjects: 115
Study 37736711 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone 8 mg in 500 mL normal saline
Number of subjects: 200
Study 37736711 — intervention group
Group type: COMPARATOR
Intervention: 500 mL normal saline
Number of subjects: 200
Study 37736793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide nanoLiposomes (CNL)
Number of subjects: 15
Study 37736959 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice
Number of subjects: 40
Study 37736959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37736966 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional-collective-community-based incentives (C3Is) provided to community groups in HRUCs based on reduction in polio vaccine refusals.
Number of subjects: 0
Study 37736981 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple linear regression predicting X-nuclear transmit gain based on proton body coil data.
Number of subjects: 156
Study 37737050 — intervention group
Group type: EXPERIMENTAL
Intervention: HUBER rehabilitation group (HUB) with physiotherapy, balneotherapy and HUBER exercises
Number of subjects: 70
Study 37737050 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation group (STAND) with physiotherapy, balneotherapy and cycloergometer exercises
Number of subjects: 70
Study 37737114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullabies sung by mothers
Number of subjects: 51
Study 37737114 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 51
Study 37737114 — intervention group
Group type: COMPARATOR
Intervention: Routine care with no music
Number of subjects: 51
Study 37737132 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and CT measurements
Number of subjects: 0
Study 37737132 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pulmonary function
Number of subjects: 0
Study 37737132 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging texture-features
Number of subjects: 0
Study 37737952 — intervention group
Group type: EXPERIMENTAL
Intervention: IXEQ4W (80 mg every 4 weeks, starting dose 160 mg)
Number of subjects: 147
Study 37737952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 37737952 — intervention group
Group type: EXPERIMENTAL
Intervention: IXEQ4W (overall study population)
Number of subjects: 147
Study 37737952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (overall study population)
Number of subjects: 147
Study 37737952 — intervention group
Group type: EXPERIMENTAL
Intervention: IXEQ4W
Number of subjects: 147
Study 37737952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to IXEQ4W)
Number of subjects: 147
Study 37737962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNβ-1a) exposure during early pregnancy
Number of subjects: 302
Study 37737962 — intervention group
Group type: COMPARATOR
Intervention: Control group from the Metropolitan Atlanta Congenital Defects Program (MACDP)
Number of subjects: 302
Study 37737966 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone nasal spray administration by lay citizens
Number of subjects: 0
Study 37737966 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency response
Number of subjects: 0
Study 37738028 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-1 and entrectinib
Number of subjects: 6
Study 37738052 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care augmented by telemedicine decision support (n=13,274)
Number of subjects: 26254
Study 37738052 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group; n=12,980)
Number of subjects: 26254
Study 37738081 — intervention group
Group type: EXPERIMENTAL
Intervention: ThoughtFullChat app (text-based coaching with certified mental health professionals)
Number of subjects: 392
Study 37738081 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 392
Study 37738088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (Flu), thiotepa (Thio), and busulfan (Bu)
Number of subjects: 191
Study 37738088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (Flu), thiotepa (Thio), and treosulfan (Treo)
Number of subjects: 191
Study 37738125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (230 mg/m2 twice daily)
Number of subjects: 59
Study 37738155 — intervention group
Group type: EXPERIMENTAL
Intervention: InCharge Health
Number of subjects: 293
Study 37738155 — intervention group
Group type: COMPARATOR
Intervention: HU Toolbox
Number of subjects: 293
Study 37738153 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected patients with CRAb
Number of subjects: 842
Study 37738153 — intervention group
Group type: COMPARATOR
Intervention: Non-infected patients
Number of subjects: 842
Study 37738153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 842
Study 37738153 — intervention group
Group type: EXPERIMENTAL
Intervention: Other types of infection
Number of subjects: 842
Study 37738153 — intervention group
Group type: EXPERIMENTAL
Intervention: CG2 strains
Number of subjects: 842
Study 37738153 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-CG2 strains
Number of subjects: 842
Study 37738237 — intervention group
Group type: EXPERIMENTAL
Intervention: selfBACK app adjunct to usual care
Number of subjects: 461
Study 37738237 — intervention group
Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 461
Study 37738323 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Health interventions in Cancer and Palliative Care
Number of subjects: 0
Study 37738329 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK-250, a Novel siRNA-Based Oligonucleotide
Number of subjects: 0
Study 37738368 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Infrared Photobiomodulation Therapy
Number of subjects: 0
Study 37738368 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37738626 — intervention group
Group type: EXPERIMENTAL
Intervention: FPDMM patients with RUNX1 variants
Number of subjects: 214
Study 37738655 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRαβ/CD19 cell depletion
Number of subjects: 213
Study 37738676 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune monitoring-guided antiviral prophylaxis
Number of subjects: 193
Study 37738676 — intervention group
Group type: COMPARATOR
Intervention: Fixed duration of antiviral prophylaxis (180 days for CMV-seronegative or 90 days for CMV-seropositive)
Number of subjects: 193
Study 37739167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA)
Number of subjects: 0
Study 37739167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37739426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted CXL
Number of subjects: 11
Study 37739426 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted CXL (truly progressive disease)
Number of subjects: 11
Study 37739466 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (6 g) and Vitamin D
Number of subjects: 90
Study 37739466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 90
Study 37739475 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital assessment unit (PAU)
Number of subjects: 10849
Study 37739475 — intervention group
Group type: COMPARATOR
Intervention: Non-PAU assessed patients (Control)
Number of subjects: 10849
Study 37739476 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based recreational experiences offered during hospitalisation
Number of subjects: 124
Study 37739476 — intervention group
Group type: COMPARATOR
Intervention: Standard care without VR-based recreational experiences
Number of subjects: 124
Study 37739573 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol 400 mg three times daily (1200 mg/day) for 20 months
Number of subjects: 150
Study 37739573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 37739573 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 150
Study 37739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation plus exercise (n=70)
Number of subjects: 311
Study 37739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham cognitive rehabilitation plus exercise (n=71)
Number of subjects: 311
Study 37739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation plus sham exercise (n=76)
Number of subjects: 311
Study 37739574 — intervention group
Group type: COMPARATOR
Intervention: Sham cognitive rehabilitation and sham exercise (n=67)
Number of subjects: 311
Study 37739572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg orally per day
Number of subjects: 78
Study 37739572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 37739572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 78
Study 37739684 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored nutritional guidance provided by a clinical nutritionist
Number of subjects: 63
Study 37739681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhoea
Number of subjects: 100
Study 37739681 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation
Number of subjects: 100
Study 37739688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention focusing on healthy eating according to Norwegian food-based dietary guidelines
Number of subjects: 383
Study 37739706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Grip (HG) dynamometer measurement for muscle strength
Number of subjects: 341
Study 37739706 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of malnutrition according to GLIM criteria
Number of subjects: 341
Study 37739706 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for sarcopenia in primary care
Number of subjects: 341
Study 37739719 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) scores ≤98
Number of subjects: 224
Study 37739719 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI)
Number of subjects: 224
Study 37739769 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival-limbal autograft (CLAu)
Number of subjects: 61
Study 37739769 — intervention group
Group type: COMPARATOR
Intervention: Mini-simple limbal epithelial transplantation (mini-SLET)
Number of subjects: 61
Study 37739792 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg twice a day on day 1, 800 mg twice a day on days 2 to 5)
Number of subjects: 1246
Study 37739792 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (average Cmin ≥20 µg/mL)
Number of subjects: 1246
Study 37739792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study 37739939 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 30, 45 or 60 mg/m² combined with ipilimumab
Number of subjects: 0
Study 37739939 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone (control not explicitly mentioned)
Number of subjects: 0
Study 37740001 — intervention group
Group type: EXPERIMENTAL
Intervention: Expect Adderall/receive placebo
Number of subjects: 121
Study 37740001 — intervention group
Group type: EXPERIMENTAL
Intervention: Expect Adderall/receive 200 mg caffeine
Number of subjects: 121
Study 37740001 — intervention group
Group type: COMPARATOR
Intervention: Expect/receive no drug (control)
Number of subjects: 121
Study 37740107 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive sodium hypochlorite/amino acid and xHyA gels
Number of subjects: 48
Study 37740107 — intervention group
Group type: COMPARATOR
Intervention: SRP (control)
Number of subjects: 48
Study 37740111 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cell therapy (ACT)
Number of subjects: 1700
Study 37740179 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV infection of primary lymphatic endothelial cells (LECs)
Number of subjects: 19
Study 37740179 — intervention group
Group type: COMPARATOR
Intervention: Knock-down of STC1 or FLT4 in LECs
Number of subjects: 19
Study 37740419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) associated with the best medical treatment (BMT)
Number of subjects: 488
Study 37740419 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 488
Study 37740442 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behaviour therapy (iCBT)
Number of subjects: 144
Study 37740442 — intervention group
Group type: COMPARATOR
Intervention: online discussion forum (ODF)
Number of subjects: 144
Study 37740448 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone acetate 1 mL (40 mg) plus 2 mL lidocaine (1%))
Number of subjects: 31
Study 37740448 — intervention group
Group type: COMPARATOR
Intervention: Control (1 mL saline and 2 mL lidocaine)
Number of subjects: 31
Study 37740554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (35 mg/kg) plus 1200 mg/day of linezolid for 28 days, then reduced to 600 mg/day
Number of subjects: 30
Study 37740581 — intervention group
Group type: EXPERIMENTAL
Intervention: GP40141 (3 ug × kg)
Number of subjects: 56
Study 37740581 — intervention group
Group type: COMPARATOR
Intervention: Reference romiplostim
Number of subjects: 56
Study 37740588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, lenalidomide, and ibrutinib (R2I)
Number of subjects: 0
Study 37740611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4017 (selective 11β-HSD1 inhibitor)
Number of subjects: 0
Study 37740611 — intervention group
Group type: COMPARATOR
Intervention: Urinary (5αTHF + THF)/THE ratio
Number of subjects: 0
Study 37740725 — intervention group
Group type: COMPARATOR
Intervention: Maternal total CB-PTSS score at T1
Number of subjects: 0
Study 37740871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi) during the maintenance period
Number of subjects: 31
Study 37740871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi)
Number of subjects: 31
Study 37740874 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss treatment (BWL) for 24 weeks
Number of subjects: 32
Study 37740923 — intervention group
Group type: COMPARATOR
Intervention: Sparse MC-FC coupling index
Number of subjects: 137
Study 37740923 — intervention group
Group type: COMPARATOR
Intervention: Abnormal coupling strength
Number of subjects: 137
Study 37740921 — intervention group
Group type: EXPERIMENTAL
Intervention: Female mutation carriers
Number of subjects: 325
Study 37740921 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic female carriers
Number of subjects: 325
Study 37740921 — intervention group
Group type: COMPARATOR
Intervention: PiB PET and established CSF AD markers
Number of subjects: 325